### Edgar Filing: AMARIN CORP PLC\UK - Form 4

AMARIN C	ORP PLC\UK											
Form 4												
June 21, 201	.3											
FORM	14									OMB AF	PPROVAL	
	UNITE	D STATES				ND EXC D.C. 205		NGE C	COMMISSION	OMB Number:	3235-0287	
Check th	ner									Expires:	January 31, 2005	
subject to <b>STATEMENT OF CHAN</b>					GES IN BENEFICIAL OWNERSHI					Estimated average		
Section 1	tion 16. SECUI					ITIES			burden hours per			
Form 4 o Form 5		urguant to	Saction 1	6(a) of	tha	Soouriti	oc Ev	cohona	a $\Lambda$ at of 1024	response	0.5	
obligatio	ns Section 1							•	e Act of 1934, f 1935 or Section	n		
may cont See Instruction	unue.		of the In	•		•	• •					
l(b).	Deemongee											
(Print or Type I	Kesponses)											
$7 \cdot 1 \cdot \dots \cdot 1 \cdot 1 \cdot \dots \cdot 1 \cdot C$				2. Issuer Name <b>and</b> Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer			
AM			AMAR	MARIN CORP PLC\UK [AMRN]					(Check all applicable)			
(Last)	(First)	(Middle)	3. Date of	Earliest	Tra	insaction			× ×	11	,	
			(Month/D	-	)				X Director X Officer (give		Owner er (specify	
	RIN PHARMA, ROUTE 206, S		06/21/2	013					below)	below)		
11(C., 1450	KOU I L 200, 5	JUIL 200							Chief I	Executive Offic	er	
(Street) 4				4. If Amendment, Date Original					6. Individual or Joint/Group Filing(Check			
			Filed(Mor	th/Day/Y	ear)				Applicable Line) _X_ Form filed by (	One Reporting Pe	rson	
BEDMINS	ГER, NJ 07921									fore than One Re		
(City)	(State)	(Zip)	Tabl	e I - Non	1-De	erivative S	Securit	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ned n Date, if Day/Year)	Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) y/Year) (Instr. 8)				of (D)	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
				Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Ordinary Shares $(1)$	06/21/2013			М		10,000	A	\$ 1.35	131,937	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: AMARIN CORP PLC\UK - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. D So (I
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 1.35	06/21/2013		М	10,000	(2)	12/21/2019	Ordinary Shares (1)	10,000	

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
	Director	10% Owner	Officer	Other				
Zakrzewski Joseph S C/O AMARIN PHARMA, INC. 1430 ROUTE 206, SUITE 200 BEDMINSTER, NJ 07921	Х		Chief Executive Officer					
Signatures								
/s/ Frederick Ahlholm, by power o attorney	f	06/21	/2013					
**Signature of Reporting Person		Da	ite					

# **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (1)

On December 21, 2009, the Reporting Person was granted an option to purchase 1,170,000 ordinary shares under the Amarin Corporation plc 2002 Stock Option Plan. The stock option initially vested in four equal annual installments beginning on January 1,

(2) 2010. In December 2010, the Issuer's Board of Directors approved the acceleration of the vesting of this award by six months such that the option vested in four equal installments and became fully vested on July 1, 2012.

### **Remarks:**

As of the date of this Form 4, the Reporting Person owns or holds the right to acquire, subject to vesting conditions, an aggreg

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.